Overview / Abstract: |
STATEMENT OF NEED An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatments targeting HER2 are some of the most recent additions to the arsenal of targeted therapy for this disease. This activity chaired by Christopher Lieu, MD, Associate Director of Clinical Research at the University of Colorado Cancer Center, will provide expert perspectives and practical guidance on treating HER2-positive metastatic CRC. TARGET AUDIENCE Oncologists, gastroenterologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with colorectal cancer (CRC). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: |
Expiration |
Jun 12, 2024 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 CME | 1.0 NCPD | MOC | ILNA |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Rahul Banerjee, MD, FACP |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Seagen. |
Keywords / Search Terms |
i3 Health Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, CE, oncology, clinical data, colorectal cancer, colorectal, Oncologists, gastroenterologists, nurse practitioners, physician assistants, oncology nurses, nurses, CRC Free CE CME |